Answers are grounded in this paper and cite their sources.
Background: Osteoarthritis (OA) is a degenerative joint disease affecting millions globally, often leading to pain and reduced mobility. Nutraceuticals like undenatured chicken collagen are gaining attention for their potential in symptom relief. This proof-of-concept study evaluates the clinical efficacy of Unstergen® of Titan Biotech Limited in the management of OA. Methods: This randomised, double-blind, placebo-controlled study studies 48 adults with OA. Subjects received 40 mg/day of Unstergen® (n=32) or placebo (n=16) once a day for 90 days. Outcomes were assessed using WOMAC score, pain scale, quality of life questionnaire (QoL) for all and global rating of change scale (GROC) using X ray of target joint for a cohort of 12 subjects. Results: Unstergen group demonstrated statistically significant reduction of 20.39% in Western Ontario and McMaster universities osteoarthritis index (WOMAC) scores and 37.77% in pain numerical rating scale (Pain NRS) compared to 7.24% and 8.70% reduction in the placebo arm, respectively. The 90.32% subjects reported improvement in QoL compared to placebo (p<0.05). The 87.50% subjects were deemed to have marked improvement on their X ray while no subject in the placebo arm showed improvement after 90 days. No adverse event was attributed to Unstergen and was deemed clinically safe. Conclusions: Unstergen® demonstrated significant improvement in pain, function and QoL; highlighting its role as a novel nutraceutical supplementation therapy for OA.
No takes yet. Share an insight, caveat, or question.
V. T. Sriraam (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: